The companies will work closely to introduce CapsiAtra into innovative and novel applications, with the target sectors identified as weight management products and sports nutrition.
The ingredient is described as a dihydrocapsiate compound naturally found in CH-19 Sweet peppers that holds clinical benefits in weight management, endurance and metabolism. It can be used in ready-to-mix, capsule and tablet applications. In addition to numerous human clinical trials, the ingredient has also received a letter of no objection from the FDA in regards to its GRAS safety dossier.
“As an innovative ingredient with impressive scientific support, CapsiAtra will be an excellent addition to our product line,” said Kevin Meyer, Vice President of Sales and Business Development for Glanbia Nutritionals.
“We are very pleased with our strategic partnership with Glanbia Nutritionals in terms of one of our most valuable specialty ingredients: CapsiAtra,” said Tak Kuwashima, General Manager of Ajinomoto Co., Inc. “Glanbia’s nutritional expertise and sales team will open doors for CapsiAtra and allow us to enter into new and innovative markets that have been longing for scientifically proven ingredients in terms of both safety and efficacy.”